Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.44 |
| ▸ | GABRD | O14764 | 5/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.44 |
| ▸ | GABRE | P78334 | 5/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759725 | 0.89 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1701309 | 0.87 | NPC1 (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12045650 | 0.84 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1704471 | 0.84 | PDE10A (0.37) | PDE10ANPC1KDM4EALDH1A1TP53 | |
| SCHEMBL1701332 | 0.78 | PDE10A (0.37) | PDE10ANPC1KDM4EALDH1A1TP53 | |
| SCHEMBL1701147 | 0.77 | PGR (0.38) | PDE10ANPC1KDM4EALDH1A1TP53 | |
| SCHEMBL23123437 | 0.77 | SMN1; SMN2 (0.45) | NPC1KDM4EALDH1A1TP53MAPT | |
| SCHEMBL9981390 | 0.76 | PDE10A (0.36) | PDE10ANPC1MAPT | |
| SCHEMBL9980956 | 0.75 | KDM4E (0.44) | NPC1KDM4EALDH1A1TP53MAPT | |
| SCHEMBL28500973 | 0.75 | NPC1 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | GABRP 1035/4885GABRD 656/4885GABRA1 1005/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | GABRP 814/4885GABRD 208/4885GABRA1 336/4885 |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | GABRP 814/4885GABRD 208/4885GABRA1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.